Quantifying, Visualizing, and Monitoring Lead Optimization.
暂无分享,去创建一个
[1] Abhyuday Mandal,et al. Identifying Promising Compounds in Drug Discovery: Genetic Algorithms and Some New Statistical Techniques. , 2007 .
[2] R. Hamatake,et al. Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound. , 2014, Journal of medicinal chemistry.
[3] Claude E. Shannon,et al. Prediction and Entropy of Printed English , 1951 .
[4] G. Derringer,et al. Simultaneous Optimization of Several Response Variables , 1980 .
[5] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[6] R. Hamatake,et al. Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. , 2014, Journal of medicinal chemistry.
[7] R. Hamatake,et al. Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A , 2013, Antimicrobial Agents and Chemotherapy.
[8] J Willem M Nissink,et al. Analyzing compound and project progress through multi-objective-based compound quality assessment. , 2013, Future medicinal chemistry.
[9] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[10] Theodore T. Allen,et al. An alternative desirability function for achieving ‘six sigma’ quality , 2003 .
[11] N. Meanwell,et al. Introduction to hepatitis C virus (HCV) therapies special thematic issue. , 2014, Journal of medicinal chemistry.
[12] F. Mosteller,et al. Understanding robust and exploratory data analysis , 1985 .
[13] R. Esteban,et al. Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.
[14] C. Moore,et al. Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents. , 2014, Journal of medicinal chemistry.
[15] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[16] William T. Scherer,et al. "The desirability function: underlying assumptions and application implications" , 1998, SMC'98 Conference Proceedings. 1998 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.98CH36218).
[17] N. Meanwell. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.
[18] Nate Silver,et al. The signal and the noise : why so many predictions fail but some don't , 2012 .
[19] Kwang-Jae Kim,et al. Expected Desirability Function: Consideration of Both Location and Dispersion Effects in Desirability Function Approach , 2007 .
[20] John J. Peterson. A Posterior Predictive Approach to Multiple Response Surface Optimization , 2004 .
[21] D. J. Price,et al. Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization. , 2012, ACS medicinal chemistry letters.
[22] A. Hopkins,et al. The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.
[23] D. J. Price,et al. Hepatitis C replication inhibitors that target the viral NS4B protein. , 2014, Journal of medicinal chemistry.